Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics (ASRT)
:ASRT
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2025
|% Change Since: -11.54%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights significant achievements, particularly in the growth of Rolvedon sales and strategic leadership appointments, which position the company for future growth. However, challenges such as the erosion of Indocin sales, increased legal expenses, and adjusted EBITDA falling below expectations indicate areas of concern. The strategic focus for 2025 aims to address these challenges and achieve transformation.Company Guidance
During the Assertio Holdings Full Year 2024 Results Conference Call, the company provided guidance for 2025, emphasizing their year of transformation. The guidance includes expected net sales ranging from $108 million to $123 million and adjusted EBITDA between $10 million and $19 million. The company highlighted a focus on strategic priorities, including simplifying structure and processes, focusing on growth assets like Rolvedon and Sympazan, and reducing legal exposure to lower operating expenses. Additionally, Assertio aims to deploy capital strategically for long-term value generation. The call also mentioned a modest growth expectation for Rolvedon, with double-digit growth for Sympazan anticipated, despite the continued decline of Indocin sales. The company remains engaged in strategic discussions for potential acquisitions, though specific details were not disclosed.Rolvedon Sales Achievement
Rolvedon sales exceeded $60 million, indicating strong growth and successful transition as the lead asset. This was complemented by positive results from the Rolvedon same-day dosing trial.
Financial Performance Highlights
Total product sales reached $120.8 million, at the high end of the guidance range. Full year adjusted EBITDA was $17.1 million, and operating cash flows were $26.4 million, exceeding the high-end cash goal of $100 million.
Strategic Appointments and Leadership Strengthening
Assertio strengthened its leadership team with the appointment of Mary Pietryga as Chief Commercial Officer and Paul Schwichtenberg as Chief Transformation Officer.
---
ASRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ASRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 12, 2025 | $0.78 | $0.72 | -7.69% |
| Nov 11, 2024 | $0.92 | $0.85 | -7.61% |
| Aug 07, 2024 | $1.23 | $1.08 | -12.20% |
| May 06, 2024 | $1.22 | $1.11 | -9.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Assertio Therapeutics (ASRT) report earnings?
Assertio Therapeutics (ASRT) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Assertio Therapeutics (ASRT) earnings time?
Assertio Therapeutics (ASRT) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASRT EPS forecast?
ASRT EPS forecast for the fiscal quarter 2025 (Q1) is -0.06.
---